Intellia Therapeutics, Inc. $NTLA Shares Sold by Amova Asset Management Americas Inc.

Amova Asset Management Americas Inc. reduced its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 10.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,973,061 shares of the company’s stock after selling 219,400 shares during the quarter. Amova Asset Management Americas Inc.’s holdings in Intellia Therapeutics were worth $25,275,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the business. ARK Investment Management LLC raised its stake in shares of Intellia Therapeutics by 19.2% in the 4th quarter. ARK Investment Management LLC now owns 14,207,324 shares of the company’s stock valued at $127,724,000 after acquiring an additional 2,288,146 shares during the period. Vanguard Group Inc. boosted its position in Intellia Therapeutics by 17.8% during the 4th quarter. Vanguard Group Inc. now owns 13,010,001 shares of the company’s stock worth $116,960,000 after purchasing an additional 1,965,181 shares during the period. State Street Corp increased its holdings in Intellia Therapeutics by 29.1% in the 4th quarter. State Street Corp now owns 6,418,836 shares of the company’s stock valued at $57,705,000 after purchasing an additional 1,447,967 shares in the last quarter. Geode Capital Management LLC increased its holdings in Intellia Therapeutics by 4.1% in the 4th quarter. Geode Capital Management LLC now owns 2,696,187 shares of the company’s stock valued at $24,243,000 after purchasing an additional 107,333 shares in the last quarter. Finally, Two Sigma Investments LP raised its position in Intellia Therapeutics by 7.6% in the third quarter. Two Sigma Investments LP now owns 2,449,607 shares of the company’s stock valued at $42,305,000 after purchasing an additional 173,033 shares during the period. Institutional investors and hedge funds own 88.77% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on NTLA shares. HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of Intellia Therapeutics in a research note on Monday, June 15th. Chardan Capital raised their target price on Intellia Therapeutics from $27.00 to $30.00 and gave the company a “buy” rating in a report on Monday, April 27th. Morgan Stanley raised their target price on Intellia Therapeutics from $11.00 to $15.00 and gave the company an “equal weight” rating in a report on Monday, April 27th. Citizens Jmp reissued a “market outperform” rating and set a $30.00 price target on shares of Intellia Therapeutics in a research report on Monday, June 15th. Finally, Leerink Partners set a $35.00 price target on Intellia Therapeutics in a report on Monday, April 27th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, nine have assigned a Hold rating and four have assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $20.19.

Intellia Therapeutics Price Performance

Shares of Intellia Therapeutics stock opened at $10.92 on Tuesday. Intellia Therapeutics, Inc. has a 1-year low of $7.95 and a 1-year high of $28.25. The company has a market capitalization of $1.53 billion, a PE ratio of -3.08 and a beta of 1.77. The business has a 50-day moving average of $14.22 and a 200-day moving average of $13.44.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.11. The business had revenue of $15.05 million for the quarter, compared to analysts’ expectations of $13.81 million. Intellia Therapeutics had a negative return on equity of 57.47% and a negative net margin of 597.04%.During the same quarter in the previous year, the firm posted ($1.10) earnings per share. On average, equities analysts expect that Intellia Therapeutics, Inc. will post -3.18 earnings per share for the current fiscal year.

Insider Activity at Intellia Therapeutics

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,641 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $16.78, for a total value of $44,315.98. Following the transaction, the chief accounting officer directly owned 66,886 shares of the company’s stock, valued at $1,122,347.08. This represents a 3.80% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Edward J. Dulac III sold 4,677 shares of the stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $18.00, for a total value of $84,186.00. Following the transaction, the executive vice president owned 156,286 shares of the company’s stock, valued at approximately $2,813,148. This trade represents a 2.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 3.50% of the stock is owned by insiders.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.